lncRNA MIR31HG和miR-101在分化型甲状腺癌组织中的表达及临床意义

Expressions of lncRNA MIR31HG and miR-101 in differentiated thyroid cancer tissues and their clinical significance

摘要:

背景与目的 研究表明长链非编码RNA（lncRNA）与微小RNA（miRNA）的表达异常以及两者的相互作用在恶性肿瘤的发生与发展中起了重要作用。本研究探讨分化型甲状腺癌患者癌组织lncRNA MIR31HG与miR-101的表达特点，以及两者表达与患者临床病理特征及预后的关系。方法 用qRT-PCR检测92例分化型甲状腺癌患者的癌组织及癌旁组织手术标本中lncRNA MIR31HG和miR-101表达水平，收集患者的临床资料与随访资料，分析两者表达与患者临床病理因素的关系，用Kaplan-Meier法分析患者生存率，采用Cox比例风险回归模型分析患者预后不良的影响因素。结果 分化型甲状腺癌组织中lncRNA MIR31HG相对表达量明显高于癌旁组织，而miR-101相对表达量明显低于癌旁组织（均P<0.01）。lncRNA MIR31HG和miR-101相对表达量均与患者的临床分期、分化程度、淋巴结转移明显有关（均P<0.05）。lncRNA MIR31HG高表达患者的累积生存率低于lncRNA MIR31HG低表达患者（84.7% vs. 94.6%，χ²=7.032，P=0.016），miR-101低表达患者累积生存率低于miR-101高表达患者（78.3% vs. 95.6%，χ²=8.482，P=0.004）。临床分期Ⅲ~Ⅳ、分化程度高、癌组织lncRNA MIR31HG相对表达量>1.5和miR-101相对表达量<0.5是分化型甲状腺癌预后不良的危险因素（均P<0.05）。结论 分化型甲状腺癌组织中lncRNA MIR31HG表达上调与miR-101表达下调，是分化型甲状腺癌预后不良危险因素，两者可能成为分化型甲状腺癌预后不良标志物。

Abstract:

Background and Aims Studies have shown that abnormal expressions long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) and the interaction between them play important roles in the occurrence and development of malignant tumors. This study was conducted to investigate the expression characteristics of lncRNA MIR31HG and miR-101 in differentiated thyroid cancer tissues of patients, as well as their relationship with clinicopathologic features and prognosis.Methods The expression levels of lncRNA MIR31HG and miR-101 in the surgical specimens of tumor tissue and adjacent non-tumor tissue form 92 patients with differentiated thyroid cancer were detected using qRT-PCR. The clinical and follow-up data of the patients were collected, and the relationship between the expressions of these two molecules and clinicopathologic factors was analyzed. Kaplan-Meier analysis was used to analyze patient survival rates, and the Cox proportional hazards regression model was used to analyze factors for poor prognosis in patients.Results The relative expression level of lncRNA MIR31HG was significantly higher while the relative expression level of miR-101 was significantly lower in differentiated thyroid cancer tissue than those in adjacent non-tumor tissue (both P<0.01). The relative expression levels of lncRNA MIR31HG and miR-101 were significantly associated with clinical stage, differentiation degree, and lymph node metastasis of patients (all P<0.05). Patients with high expression of lncRNA MIR31HG had lower cumulative survival rates than those with its low expression (84.7% vs. 94.6%, χ²=7.032, P=0.016), and patients with low expression of miR-101 had lower cumulative survival rates than those with its high expression (78.3% vs. 95.6%, χ²=8.482, P=0.004). Clinical stage Ⅲ-Ⅳ, high differentiation degree, lncRNA MIR31HG relative expression level >1.5, and miR-101 relative expression level <0.5 were identified as risk factors for poor prognosis in differentiated thyroid cancer (all P<0.05).Conclusion Upregulation of lncRNA MIR31HG and downregulation of miR-101 in DTC tissues are risk factors for poor prognosis in differentiated thyroid cancer, suggesting that they could serve as prognostic markers for differentiated thyroid cancer.